NL-OMON52624招募中4 期
Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio study - Dose reduction of IL17 and IL23 inhibitors for psoriasis
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Plaque psoriasis (primarily)
- •Treatment for 6 months at least with IL23 or IL17 inhibitor in a normal dose
- •(dose advised by the label)
- •PASI (Psoriasis Area and Severity Index) <= 5 at inclusion and in previous 6
- •months (in previous 6 months, it should be clear from the patient record that
- •psoriasis was clear/almost clear if no PASI scores are available).
- •DLQI <= 5 at inclusion
排除标准
- •Another indication than plaque psoriasis as the main indication for biologic
- •use (e.g. receives biologic for rheumatoid arthritis as the main indication).
- •Concomitant use of systemic immunosuppressants other than methotrexate or
- •acitretin (e.g. prednisone, cyclosporine etc).
- •Severe comorbidities with short life-expectancy (e.g. metastasized tumour).
- •Presumed inability to follow the study protocol.
研究者
相似试验
进行中（未招募）
1 期
Dose reduction of IL17 and IL23 inhibitors for psoriasispsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10037155Term: Psoriasis and similar disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-004230-42-NLRadboudumc244
尚未招募
不适用
Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio studyNL-OMON29024ZonMw, KCE244
尚未招募
不适用
Dose reduction of the new generation biologicals (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio studyPsoriasisNL-OMON22341Radboudumc244
进行中（未招募）
1 期
Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trialEUCTR2017-001970-41-DKMD, PhD Salome Kristensen180
进行中（未招募）
1 期
Dose decrease of biologics for psoriasisAdult Patients diagnosed psoriasis vulgarisMedDRA version: 18.1Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10015581Term: Exacerbation of psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10037155Term: Psoriasis and similar disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10037156Term: Psoriasis flare-upSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-000943-17-NLRadboudumc120